Replimune rebounds despite analyst downgrades on FDA rejection
Source: SeekingAlpha
2025-07-23 11:34:20 ET
More on Replimune Group
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript
- Replimune Group: Analysts Are More Optimistic Than The Market
- Iovance climbs after FDA rejection for Replimune’s skin cancer drug
- Replimune plunges as FDA rejects its lead drug for skin cancer
Read the full article on Seeking Alpha
For further details see:
Replimune rebounds despite analyst downgrades on FDA rejection
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
-10.42% G/L:
$4.6493 Last:
4,448,331 Volume:
$5.06 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
